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Abstract
We report the case of a positive COVID-19 patient who presented to our hospital
for a maculopapular skin rash which appeared 7 days after the onset of COVID-19
symptoms. He was 34 years old and nothing relevant was recorded at his previous
anamnesis. The patient was hospitalized for 3 days and received systemic therapy
with steroid, antihistamines, tocilizumab, and hydroxicloroquine. On the third day of
the hospitalization the cutaneous rash had almost completely disappeared.
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1 | INTRODUCTION
A 34-year-old man was admitted to our emergency room reporting
a skin eruption had started 2 days prior. The rash was not itchy.
Seven days prior to his admission, he tested positive to the nasal
swab for Covid-19, his main symptom being a fever of 37.5C to
38C. No respiratory symptoms were present. He self-isolated at
home, upon medical recommendation. The only medication the
patient had taken at that time was Acetaminophen 1000 mg, as
needed. The blood test results were within the norm, with the
exception of C-reactive protein which was 15 mg/dL. At consulta-
tion, a generalized maculopapular eruption was observed on the
trunk, upper limbs, legs, and face without involvement of the pal-
moplantar areas.
The patient was admitted to the infectious disease ward. He was
administered intravenous steroid bolus and antihistamines. The fol-
lowing day, due to a worsening of respiratory state, the patient was
given hydroxychloroquine and an intramuscular injection of
Tocilizumab. The use of Tocilizumab has recently been suggested as a
treatment for the Cytokine Release Syndrome that can be associated
to Covid-19, particularly in younger patients.
The patient was discharged from the hospital 3 days after admis-
sion, following a complete regression of the cutaneous symptoms.
Upon discharge, antihistamines and hydroxychloroquine 200 mg/2
tablets per day were prescribed.
A photo was taken to document the skin manifestation at admis-
sion. The patient agreed to send through follow up photos via
WhatsApp (Figures 1 and 2).
2 | DISCUSSION
A cutaneous maculopapular rash may be linked to several underlying
disease/conditions. Skin reactions to Acetaminophen have been
reported in the past.1 The most frequent reactions reported are: fixed
drug eruption,2,3 Steven-Johnson/epidermal toxic necrolysis,4 and
Sweet syndrome.3
It could be said that Maculopapular eruption caused by Acetamin-
ophen is quite rare, as it is only documented in occasional publica-
tions. Maculopapular eruption may appear 7 to 14 days after
exposure to the drug. No other significant information was found in
the literature. Viral infections can present a variety of skin symptoms.
Maculopapular eruption is a well-known manifestation linked to viral
infection.
Recalcati et al recently described different skin manifesta-
tions in Covid-19 inpatients: they concluded that skin rashes are
similar to cutaneous involvement occurring during common viral
infections.
The erythematous rash was the most frequently noted.5 Other
reports on isolated cases are now emerging about different skin
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features.6,7 Skin involvement is also common in Dengue Fever
(DF) and seen in almost 50% to 82% patients.
Asymptomatic maculopapular rash and morbilliform eruptions,
not extending to palms and soles, are usually noted 3 to 6 days after a
fever. The skin rash can heal completely or become generalized and
involve dorsum of hands and feet, without extending to the palmo-
plantar regions, and lasting several days. Skin rash in DF is thought to
be caused by virus-induced injury of smaller blood vessels.8 Covid-19
has skin manifestation, such as erythematosus rash, that can be misdi-
agnosed as DF. Covid-19 also has other skin manifestation in common
with DF.6
In the case described, the patient received anti-inflammatory
drug, therefore, it is not possible to establish which was the cause of
the cutaneous rash. However, it is important to keep in mind that
Covid-19 patients may present skin rashes and/or skin lesions that
should be managed accordingly.
Further studies are needed for those Covid-19 patients who ini-
tially only present a skin rash, unique clinical symptoms, or are asymp-
tomatic and potential carriers of the virus. Further studies are also
required to determine the correlation (or lack thereof) between
Covid-related skin manifestations and organ involvement; and
whether skin manifestations can be considered a predictor of
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